Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012;7(8):e42701.
doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

Christine Schmucker  1 , Christoph Ehlken, Hansjuergen T Agostini, Gerd Antes, Gerta Ruecker, Monika Lelgemann, Yoon K Loke
Affiliations
Meta-Analysis

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

Christine Schmucker et al. PLoS One. 2012.

Abstract

Background: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk.

Methods and findings: Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. We included RCTs with a minimum follow-up of one year which investigated bevacizumab or ranibizumab in direct comparison or against any other control group (indirect comparison). Direct comparison (3 trials, 1333 patients): The one year data show a significantly higher rate of ocular adverse effects (AE) with bevacizumab compared to ranibizumab (RR = 2.8; 95% CI 1.2-6.5). The proportion of patients with serious infections and gastrointestinal disorders was also higher with bevacizumab than with ranibizumab (RR = 1.3; 95% CI 1.0-1.7). Arterial thromboembolic events were equally distributed among the groups. Indirect comparison: Ranibizumab versus any control (5 trials, 4054 patients): The two year results of three landmark trials showed that while absolute rates of serious ocular AE were low (≤ 2.1%), relative harm was significantly raised (RR = 3.1; 95% CI 1.1-8.9). A significant increase in nonocular haemorrhage was also observed with ranibizumab (RR = 1.7; 95% CI 1.1-2.7). Bevacizumab versus any control (3 trials, 244 patients): We were unable to judge the safety profile of bevacizumab due to the poor quality of AE monitoring and reporting in the trials.

Conclusions: Evidence from head-to-head trials raises concern about an increased risk of ocular and multiple systemic AE with bevacizumab. Therefore, clinicians and patients should continue to carefully weight up the benefits and harms when choosing between the two treatment options. We also emphasize the need for studies that are powered not just for efficacy, but for defined safety outcomes based on the signals detected in this systematic review.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow chart of literature search and study selection.
Figure 2
Figure 2. Forest plots: pooled results of head-to-head studies for different safety outcomes.
Figure 3
Figure 3. Forest plots: pooled results of RCTs for ranibizumab (any dose vs any control) for different safety outcomes.
Figure 4
Figure 4. Forest plots: pooled results of ranibizumab 0.3 mg vs 0.5 mg for different safety outcomes.
See this image and copyright information in PMC

References

    1. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900–1901. - PubMed
    1. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, et al. (1977) The Framingham Eye Study: I. Outline and major prevalence findings. Am J Epidemiol 106: 17–32. - PubMed
    1. Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640–1642. - PubMed
    1. Steinbrook R (2006) The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355: 1409–1412. - PubMed
    1. US Food and Drug Administration (FDA) MedWatch (2005) Safety: Avastin (bevacizumab). Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma... via the Internet. Accessed 20 February 2012.